Does Nayzilam Stop Seizures?
Nayzilam, a nasal spray form of midazolam, is FDA-approved to treat seizure clusters in patients aged 12 and older. It works by enhancing GABA activity in the brain to rapidly stop or reduce ongoing seizures. Clinical trials showed it terminated 53.4% of seizure clusters within 10 minutes, compared to 34.1% with placebo.[1][2]
How Quickly Does Nayzilam Work?
The spray delivers midazolam directly through the nasal mucosa, achieving peak blood levels in about 10-20 minutes. In a key phase 3 trial (ARTEMIS1), 73.2% of treated clusters ended within 30 minutes, with effects lasting up to 60 minutes. Patients can use a second dose after 10 minutes if seizures persist.[1][3]
What Do Real-World Studies Show?
Post-approval data from over 4,000 seizure clusters confirm similar efficacy: 54% terminated within 10 minutes and 71% within 30 minutes. It performs consistently across ages 12-65 and seizure types like focal or generalized onset.[2][4] Limitations include less data in patients under 12 or those with frequent clusters.
Who Can't Use Nayzilam or When Does It Fail?
It's ineffective or risky for acute repetitive seizures caused by metabolic issues, alcohol withdrawal, or concurrent opioids (risks respiratory depression). Contraindications include glaucoma, severe lung disease, or pregnancy (category C). If seizures don't stop after two doses, seek emergency care—it's not for status epilepticus.[1][5]
How Does Nayzilam Compare to Diastat and Other Rescue Meds?
| Treatment | Form | Onset | Termination Rate (30 min) | Key Notes |
|-----------|------|--------|---------------------------|-----------|
| Nayzilam (midazolam) | Nasal spray | 10 min | 73% | Easy self-admin; no refrigeration |
| Diastat (diazepam) | Rectal gel | 10-15 min | 55-74% | Requires caregiver; needs fridge |
| Valtoco (diazepam) | Nasal spray | 10 min | 71% | Similar to Nayzilam; generic pending |
| Intranasal lorazepam | Nasal (off-label) | 15-20 min | ~60% | Cheaper but less studied |
Nayzilam edges out rectal options for convenience, especially for teens/adults.[3][6]
Common Side Effects and Safety Concerns
Somnolence (23%), headache (10%), and nasal discomfort (6%) occur most often. Serious risks: respiratory depression (monitor breathing 3-4 hours post-dose), especially with opioids. Overuse can lead to tolerance. Long-term data shows no major cognitive impacts in epilepsy patients.[1][4]
Cost, Access, and Patent Status
A single-dose kit costs $700-900 without insurance; patient assistance covers most copays. UCB holds patents until 2034-2037, delaying generics—check DrugPatentWatch.com for updates.[7][8]
Sources
[1]: Nayzilam Prescribing Information (FDA)
[2]: Epilepsy Study Solution - Nayzilam Outcomes
[3]: New England Journal of Medicine - ARTEMIS1 Trial
[4]: UCB Nayzilam Post-Marketing Data
[5]: FDA Warnings on Benzodiazepines
[6]: Epilepsy Foundation Comparison
[7]: GoodRx Pricing
[8]: DrugPatentWatch - Nayzilam